Wu ZQ, Zhu YX, Jin Y, Zhan YC. Exosomal miRNA in early-stage hepatocellular carcinoma. World J Clin Cases 2023; 11(3): 528-533 [PMID: 36793641 DOI: 10.12998/wjcc.v11.i3.528]
Corresponding Author of This Article
Yin-Chu Zhan, MD, Director, Surgeon, Department of Surgery, The Second People's Hosptal of Quzhou, No. 338 Xin'an Avenue, Qujiang District, Quzhou 324000, Zhejiang Province, China. qzhospzyc@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jan 26, 2023; 11(3): 528-533 Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.528
Exosomal miRNA in early-stage hepatocellular carcinoma
Zhi-Qiang Wu, Yi-Xin Zhu, Yun Jin, Yin-Chu Zhan
Zhi-Qiang Wu, Yi-Xin Zhu, Yin-Chu Zhan, Department of Surgery, The Second People's Hosptal of Quzhou, Quzhou 324000, Zhejiang Province, China
Yun Jin, Department of Surgery, The Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 310009, Zhejiang Province, China
Author contributions: Wu ZQ and Zhu YX designed and reviewed the manuscript; Wu ZQ, Zhu YX, and Jin Y wrote the paper; All authors read and approved the manuscript; Wu ZQ and Zhu YX contributed equally to this work.
Conflict-of-interest statement: We declare that we have no conflict of interest related to this work.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yin-Chu Zhan, MD, Director, Surgeon, Department of Surgery, The Second People's Hosptal of Quzhou, No. 338 Xin'an Avenue, Qujiang District, Quzhou 324000, Zhejiang Province, China. qzhospzyc@163.com
Received: October 28, 2022 Peer-review started: October 28, 2022 First decision: December 19, 2022 Revised: December 26, 2022 Accepted: January 5, 2023 Article in press: January 5, 2023 Published online: January 26, 2023 Processing time: 90 Days and 11.8 Hours
Abstract
The incidence and mortality of hepatic carcinoma (HCC) remain high, and early diagnosis of HCC is seen as a key approach in improving clinical outcomes. However, the sensitivity and specificity of current early screening methods for HCC are not satisfactory. In recent years, research around exosomal miRNA has gradually increased, and these molecules have emerged as attractive candidates for early diagnosis and treatment of HCC. This review summarizes the feasibility of using miRNAs in peripheral blood exosomes as early diagnostic tools for HCC.
Core Tip: The prognosis of hepatic carcinoma (HCC) is poor and surgical resection is the only potential radical cure. Early diagnosis of HCC is a key approach in improving clinical outcomes. However, the sensitivity and specificity of current early screening methods for HCC are not satisfactory. Exosomal miRNAs have become a candidate for early diagnosis and treatment of HCC. This review summarizes the feasibility of using miRNAs in peripheral blood exosomes as early diagnostic tools for HCC.
